"Oncomicrobiotics" Affect the Efficacy of Chemotherapy

Share this content:
The presence of intestinal bacteria may improve the efficacy of chemotherapies containing alkylating agents such as cyclophosphamide.
The presence of intestinal bacteria may improve the efficacy of chemotherapies containing alkylating agents such as cyclophosphamide.

The presence of intestinal bacteria may improve the efficacy of chemotherapies containing alkylating agents such as cyclophosphamide, according to a study published in Immunity.1

The role of bacteria in the development of cancer is largely unknown, though microbes are shown to contribute to genetic instability in colon cancer and hepatocarcinoma.2 Researchers identified 2 “oncomicrobiotics,” defined as “immunogenic commensals influencing the host-cancer equilibrium,” which may affect the efficacy of chemotherapy.

T cell activity was evaluated in 38 patients with lung or ovarian cancer. Enterococcus hirae and Barnesiella intestinihominis were shown to activate T cells, helping the body to fight cancer cells more effectively, particularly among patients with lung or ovarian cancer.

RELATED: Obese Patients Receiving Unadjusted Dose-dense Chemotherapy at Risk for Toxicities

Patients with terminal cancer resistant to chemotherapy had longer progression-free survival if the immune response associated with the bacteria was exhibited.

The authors conclude that oncomicrobiotics should be evaluated as a component to anti-cancer treatments.

References

  1. Daillere R, Vetizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 2016 Oct 4. doi: 10.1016/j.immuni.2016.09.009 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters